Prevail Therapeutics (NASDAQ:PRVL) posted its quarterly earnings data on Friday. The company reported ($0.55) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.64) by $0.09, MarketWatch Earnings reports.
Shares of PRVL opened at $9.76 on Monday. The firm’s 50 day moving average is $10.26 and its 200-day moving average is $13.62. The stock has a market capitalization of $333.94 million, a P/E ratio of -4.12 and a beta of 1.30. Prevail Therapeutics has a 12-month low of $9.02 and a 12-month high of $19.96.
A number of research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Prevail Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 21st. William Blair assumed coverage on shares of Prevail Therapeutics in a research report on Monday, September 14th. They issued an “outperform” rating and a $25.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Prevail Therapeutics in a research report on Thursday, September 10th. They issued an “overweight” rating and a $26.00 price target on the stock. Oppenheimer restated a “buy” rating and issued a $25.00 price target on shares of Prevail Therapeutics in a research report on Wednesday, September 23rd. Finally, Zacks Investment Research downgraded shares of Prevail Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 14th. Two research analysts have rated the stock with a sell rating and eight have given a buy rating to the company. Prevail Therapeutics currently has a consensus rating of “Buy” and an average target price of $22.75.
Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.
Featured Story: FTSE 100 Index
Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.